Member Info for JimiHendrix

Genomadix have signed a partnership with Thermo Fisher in the US I think. That goes to show there’s a strong market for the test.

The current rollout is to neonatal intensive care units, but I think the plan is to eventually rollout to all hospitals. When that happens I think there is a good chance it will be used for everyone being given gentamicin.

Actually gentamicin is given to both children and adults.

Gentamicin is an antibiotic used by the NHS to treat serious bacterial infections, and it can be used in both children and adults. However, the dosage and administration differ depending on age, weight, kidney function, and the type of infection.

• In adults, it’s often used for infections like sepsis, urinary tract infections, or chest infections.

• In children and newborns, it’s commonly used for severe infections like neonatal sepsis or meningitis, under close monitoring.

Because gentamicin can have side effects (notably to the kidneys and ears), it’s usually given in a hospital setting with blood level monitoring, especially in children.

Https://youtube.com/playlist?list=PLSjrQnPbVdr3xF5sO5kzwn1s8d28yJKQ2&si=zdwezqP5LqyTAvdi

https://youtube.com/playlist?list=PLSjrQnPbVdr2gHAbslkYAzEUQLfLmjoSw&si=SFe2VS-gKPnjmxRn

They’re for both tests John. 7 for MT-RNR1 and 7 for CYP2C19.

14 new videos added today, very promising signs…

https://youtube.com/@genedrivediagnosticsltd?si=WaaLeDq9S0UkcEQz

It’s fact Gloria, they’ve told us 5 new NICUs are adopting from May. The remaining income from PALOH-UK will be received for this. Additionally the existing 9 NICUs have to replenish stocks as PALOH-UK funded them for 6 months up to the end of this month.

We’ve know they are routine users so it’s reasonable to assume they will be buying another 12 months of supplies. Is it not?

That’s not fact Gloria, including the sales expected this month and from Scotland adoption they will have cash to the end of the year. This doesn’t take into account likely further sales of CYP2C19 (implementation guide for NHS expected this month as well as CEIVD for selling in Europe and ME).

Yes for MTRNR1 they now have conditional NICE recommendation, and soon to be full recommendation. Full rollout adoption in Scotland from October, 5 new NUCUs adopting in the next 2 weeks and re supplying the existing 9 NICUs also expected by the end of this month (that’s likely £750k income by May)

Being quoted well over the ASK currently, 1.56 to buy a reasonable amount and no quote available for a small amount. This usually results in the share price rising.

Of course CE-IVD has commercial value, it unlocks a huge market …lol or do you mean the certificate document itself is not something they can sell.

So many derampers now, they really don’t want the share price to go up. Will likely see a huge rise from this low share price, as more commercial news flows in this month and the coming weeks/months.

Should see the following sales income (£750) arrive in the next couple of weeks…

- [ ] £250k for the 5 new NICUs going live from May as part of PALOH-UK group 2 (Group 2, the remaining five sites, with phased go-live from May 25.)

- [ ] £450k for restocking the 9 existing NICUs should in theory be restocking 12 months supplies in April as their 6 months funding runs out May

More like structured deramping going on! …it’s clear interest is picking up here, people trying to push the price down for an even lower entry. I can see this flying in the next week or two, simply not worth being out with the upcoming news and sales.

- Regulatory certification (CE-IVD under IVDR) on track for April 2025

- Ahead of CE-IVD certification we have invested significant resources in defining the market access and reimbursement routes in target European & Middle East countries, onboarding of qualified distributors and are progressing through early stages of customer adoption sites, inclusive of conversion of distributors and users considering using the comparator PoC test to ours.

- Additional distributor sites - Distributors contracted in key international geographies, with site installations in Italy and Saudi Arabia and additional (distributor) sites expected near-term.

- Implementation guide and toolkit for NHS CYP2C19 Pilot

- 5 new NICUs going live in May

- 9 existing NICU restocking

- Initial order for Scotland

This is from December and things appear to be going to plan…

“pipeline of opportunities that, if converted, would see a significant step up in revenues during calendar year 2025 and a reduction in the level of cash burn.”

2-5 bags are quite probable if CYP2C19 is rolled out to community pharmacies. All will be revealed imo, in the implementation guide and tool kit expected this month :)

If they any left to offload and it’s 2.5 - 3p I have no problem with them offloading.

Stocksaint is referring to NICE's system where clinical guidelines were routinely checked 3 years after publication to determine if they needed updating but twisting it.

Anyway... while NICE used to review guidelines every 3 years, they now have a more flexible approach, with interim surveillance programs and rapid updates, rather than a strict 3-year cycle.

Point-of-Care

.......................

• Trend toward decentralization: There's growing NHS interest in using community pharmacies as frontline health hubs (e.g., Pharmacy First scheme). Offering pharmacogenomic tests like CYP2C19 at the point of care aligns with that vision.

Practical advantages:

• Faster results for time-critical decisions (like stroke/TIA antiplatelet choice).

• No need for cold chain logistics or central lab coordination.

• Patient convenience: walk-in access and rapid turnaround.

Lab-Based Testing — Not ideal for acute use

.........................................................................

• May be used for routine pharmacogenomic profiling (e.g. preemptive testing in primary care or polypharmacy reviews).

• Slower turnaround (~days), not suitable for acute antiplatelet decision-making post-stroke or TIA.